IP Library Granted Patent US 7,981,426
Granted Patent B2
US 7,981,426 · App. 12/538,714 · Granted Jul 19, 2011

Method for stimulating wound healing

Assignee: aTyr Pharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,981,426
App. No.
12/538,714
Granted
Jul 19, 2011
Kind
B2
Abstract

The present invention relates to a method for stimulating wound healing, and more particularly to a method for stimulating wound healing in a subject in need thereof, comprising administering to a wound of the subject an effective amount for stimulating wound healing of a composition, wherein the composition comprises p43 having an amino acid sequence set forth in SEQ ID NO: 1 or functional equivalents thereof. The composition used in the method of the present invention can be efficiently utilized for the wound healing, since p43, an effective ingredient of the composition, has an excellent effect on the wound healing by its action including the induction of macrophage/monocyte and endothelial cell re-epithelization, proliferation of fibroblasts or angiogenesis.

Claims (10)

1. A method for stimulating wound healing in a subject in need thereof, comprising: administering to a wound of the subject an effective amount of a composition for stimulating wound healing, wherein the composition comprises a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence set forth in SEQ ID NO: 1; and (b) a polypeptide having at least 80% sequence homology with the polypeptide of (a).

2. The method according to claim 1 , wherein the composition further comprises at least one selected from the group consisting of antibiotics, antihistamines, anti-inflammatory drugs, anti-viral drugs, anti-fungal drugs and growth factors.

3. The method according to claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

4. The method according to claim 1 , wherein the composition is formulated with any one form selected from the group consisting of a powder, liniment, gel, lotion, cream, ointment, paste, puff, aerosol and suppository.

5. The method of claim 1 , wherein said wound is selected from the group consisting of burn, ulcer, trauma, post-surgical, post-childbirth, chronic wound and dermatitis.

6. The method of claim 5 , wherein said burn is selected from the group consisting of sunburn, chemical burn, radiation burn and thermal burn.

7. The method of claim 5 , wherein said ulcer is selected from the group consisting of pressure ulcer, plaster ulcer and decubitus ulcer.

8. The method for claim 5 , wherein said chronic wound is selected from the group consisting of bedsores, pressure sores, diabetes-related and poor circulation-related.

9. The method of claim 5 , wherein said dermatitis is selected from the group of consisting of impetigo, intertrigo, folliculitis and eczema.

10. The method of claim 1 , wherein the polypeptide consists of the amino acid sequence set forth in SEQ ID NO:1, or consists of an amino acid sequence having at least 90% sequence identity to the polypeptide of (a).

Priority Claims (1)
KR 10-2002-0042858 · Jul 22, 2002 · national
Continuity (3)
Continuation 11829018 · Jul 26, 2007
Continuation 10623567 · Jul 22, 2003
Related Publication 20100041608A1 · Feb 18, 2010